Abstract:ABSTRACT Cystic fibrosis (CF), an inherited genetic disorder caused by mutations in the cystic fibrosis transmembrane conductance regulator gene, results in sticky and thick mucosal fluids. This environment facilitates the colonization of various microorganisms, some of which can cause acute and chronic lung infections, while others may positively impact the disease. Rothia mucilaginosa , an oral commensal, is relatively abundant in the lungs of CF patients. Recent studies have unveiled its anti-inflammatory properties using in vitro three-dimensional lung epithelial cell cultures and in vivo mouse models relevant to chronic lung diseases. Apart from this, R. mucilaginosa has been associated with severe infections. However, its metabolic capabilities and genotype-phenotype relationships remain largely unknown. To gain insights into its cellular metabolism and genetic content, we developed the first manually curated genome-scale metabolic model, i RM23NL. Through growth kinetics and high-throughput phenotypic microarray testings, we defined its complete catabolic phenome. Subsequently, we assessed the model’s effectiveness in accurately predicting growth behaviors and utilizing multiple substrates. We used constraint-based modeling techniques to formulate novel hypotheses that could expedite the development of antimicrobial strategies. More specifically, we detected putative essential genes and assessed their effect on metabolism under varying nutritional conditions. These predictions could offer novel potential antimicrobial targets without laborious large-scale screening of knockouts and mutant transposon libraries. Overall, i RM23NL demonstrates a solid capability to predict cellular phenotypes and holds immense potential as a valuable resource for accurate predictions in advancing antimicrobial therapies. Moreover, it can guide metabolic engineering to tailor R. mucilaginosa ’s metabolism for desired performance. IMPORTANCE Cystic fibrosis (CF) is a genetic disorder characterized by thick mucosal secretions, leading to chronic lung infections. Rothia mucilaginosa is a common bacterium found in various parts of the human body, acting as a normal part of the flora. In people with weakened immune systems, it can become an opportunistic pathogen, while it is prevalent and active in CF airways. Recent studies have highlighted its anti-inflammatory properties in the lower pulmonary system, indicating the intricate relationship between microbes and human health. Herein, we have developed the first manually curated metabolic model of R. mucilaginosa . Our study examined the previously unknown relationships between the bacterium’s genotype and phenotype and identified essential genes that impact the metabolism under various conditions. With this, we opt for paving the way for developing new strategies in antimicrobial therapy and metabolic engineering, leading to enhanced therapeutic outcomes in cystic fibrosis and related conditions.

Growing a cystic fibrosis-relevant polymicrobial biofilm to probe community phenotypes

Development of a Polymicrobial Colony Biofilm Model to Test Antimicrobials in Cystic Fibrosis

Modeling Cystic Fibrosis Chronic Infection Using Engineered Mucus-like Hydrogels

Improvement of a mouse infection model to capture Pseudomonas aeruginosa chronic physiology in cystic fibrosis

Mathematical Modelling of Pseudomonas Aeruginosa Biofilm Growth and Treatment in the Cystic Fibrosis Lung

Genome-scale model of Rothia mucilaginosa predicts gene essentialities and reveals metabolic capabilities

Exploring the dynamics of mixed-species biofilms involving Candida spp. and bacteria in cystic fibrosis

Mechanistic Model of Rothia mucilaginosa Adaptation toward Persistence in the CF Lung, Based on a Genome Reconstructed from Metagenomic Data

Modeling Pulmonary Cystic Fibrosis in a Human Lung Airway-on-a-chip

A chronic mouse lung infection modeling the pathophysiology and inflammation of human cystic fibrosis

Antibiotic susceptibility of cystic fibrosis lung microbiome members in a multispecies biofilm

Understanding Biofilm-Phage Interactions in Cystic Fibrosis Patients Using Mathematical Frameworks

Pseudomonas aeruginosa supports the survival of Prevotella melaninogenica in a cystic fibrosis lung polymicrobial community through metabolic cross-feeding

Microfluidic Wound Model for Studying the Behaviors of Pseudomonas Aeruginosa in Polymicrobial Biofilms

An in vitro medium for modeling gut dysbiosis associated with cystic fibrosis

Informed development of a multi‐species biofilm in chronic obstructive pulmonary disease

Developing selective media for quantification of multispecies biofilms following antibiotic treatment

Microbial community organization designates distinct pulmonary exacerbation types and predicts treatment outcome in cystic fibrosis

Challenges with drug efficacy prediction of in vitro models of biofilms infecting cystic fibrosis airway

Recreating chronic respiratory infections in vitro using physiologically relevant models

DPR-MEDIATED H O RESISTANCE CONTRIBUTES TO STREPTOCOCCI SURVIVAL IN A CYSTIC FIBROSIS AIRWAY MODEL SYSTEM